NASDAQ, ARNA - Arena Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing oral drugs in four major therapeutic areas:
cardiovascular, central nervous system, inflammatory and metabolic diseases. Our
most advanced drug candidate, lorcaserin hydrochloride, or lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
We have a broad pipeline of novel compounds that selectively target known and
orphan G protein-coupled receptors, or GPCRs, and includes compounds being
developed by our partners, Ortho-McNeil Pharmaceutical, Inc., a Johnson &
Johnson company, or Ortho-McNeil, and Merck & Co., Inc., or Merck.
We focus on GPCRs because they are a validated class of drug targets that
mediate the majority of cell-to-cell communication in humans. ...
Read SEC Filing on NASDAQ.com »